New study aims to crack the code of treatment resistance in lymphoma

NCT ID NCT07614035

Not yet recruiting Knowledge-focused Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 70 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who are receiving bispecific antibody therapy. Researchers want to understand why some patients don't respond or develop serious side effects. They will look at tumor samples, gut bacteria, and PET scans to find clues that could predict treatment success or failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bispecific antibodies (glofitamab, epcoritamab, mosunetuzumab)
What this could lead to: If successful, this could help doctors choose the best treatment for each patient and identify who might benefit most from bispecific antibody therapy.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

IRCCS Policlinico di Sant'Orsola

Bologna, Emilia-Romagna, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.